In a phase II study (WU-KONG6), sunvozertinib demonstrated an ORR of ~60 % in pretreated NSCLC patients with EGFR exon 20 insertions, with a median duration of response exceeding 9 months (Mitsudomi, 2025[85]). Here, EGFR is linked to non-small cell lung carcinoma.